Herpes virus inactivation by chemical carcinogens: differential inactivation of herpes simplex viruses by 4-nitroquinoline 1-oxide and related compounds.
Treatment of stocks of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) with the chemical carcinogen 4-nitroquinoline 1-oxide (NQO) resulted in inactivation of virus infectivity at rates which were directly dependent on the concentration of NQO and interval of exposure to NQO. HSV-1 strains were more sensitive than HSV-2 strains to inactivation by NQO, although survival curves of both HSV types were multicomponent. Exposure of HSV-2 to a related group of chemicals suggested that the structural specificity required for inactivation of this virus was similar to that established by previous in vivo carcinogenicity tests.
D015112:4-Nitroquinoline-1-oxide / Q000031:analogs & derivatives / Q000494:pharmacology*; D002273:Carcinogens / Q000494:pharmacology*; D002478:Cells, Cultured; D009600:Nitroquinolines / Q000494:pharmacology*; D018139:Simplexvirus / Q000187:drug effects* / Q000472:pathogenicity; D013997:Time Factors
D002273:Carcinogens; D009600:Nitroquinolines; D015112:4-Nitroquinoline-1-oxide